91 related articles for article (PubMed ID: 29269797)
1. Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study.
Pidala J; Chai X; Kurland BF; Inamoto Y; Flowers ME; Palmer J; Khera N; Jagasia M; Cutler C; Arora M; Vogelsang G; Lee SJ
Biol Blood Marrow Transplant; 2013 May; 19(5):784-91. PubMed ID: 23395601
[TBL] [Abstract][Full Text] [Related]
2. New and emerging therapies for acute and chronic graft
Hill L; Alousi A; Kebriaei P; Mehta R; Rezvani K; Shpall E
Ther Adv Hematol; 2018 Jan; 9(1):21-46. PubMed ID: 29317998
[TBL] [Abstract][Full Text] [Related]
3. The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
Schroeder MA; Choi J; Staser K; DiPersio JF
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1125-1134. PubMed ID: 29289756
[TBL] [Abstract][Full Text] [Related]
4. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
[TBL] [Abstract][Full Text] [Related]
5. Changes in body composition in children with acute graft-versus-host disease within the first 100 days after hematopoietic stem cell transplantation.
Feng Y; Pan LY; Shen LY; Chang PP; Zhang BH; Hong L
Eur J Clin Nutr; 2018 Aug; 72(8):1167-1175. PubMed ID: 29269889
[TBL] [Abstract][Full Text] [Related]
6. Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD - A longitudinal study.
Przybyla B; Pinomäki A; Petäjä J; Joutsi-Korhonen L; Strandberg K; Hillarp A; Öhlin AK; Ruutu T; Volin L; Lassila R
PLoS One; 2017; 12(12):e0190007. PubMed ID: 29272282
[TBL] [Abstract][Full Text] [Related]
7. Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation.
Deotare U; Atenafu EG; Loach D; Michelis FV; Kim DD; Thyagu S; Lipton JH; Messner HA; Viswabandya A
Bone Marrow Transplant; 2018 Mar; 53(3):361-365. PubMed ID: 29269806
[No Abstract] [Full Text] [Related]
8. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease.
Mehta RS; Saliba RM; Jan A; Shigle TL; Wang E; Nieto Y; Ciurea SO; Oran B; Im J; Olson A; Marin D; Qazilbash M; Khouri I; Rondon G; Anderlini P; Rezvani K; Popat U; Kebriaei P; Shpall E; Champlin R; Alousi A
Transplant Cell Ther; 2021 Mar; 27(3):272.e1-272.e5. PubMed ID: 33781539
[TBL] [Abstract][Full Text] [Related]
9. Understanding and treatment of cutaneous graft-versus-host-disease.
Hong J; Fraebel J; Yang Y; Tkacyk E; Kitko C; Kim TK
Bone Marrow Transplant; 2023 Dec; 58(12):1298-1313. PubMed ID: 37730800
[TBL] [Abstract][Full Text] [Related]
10. Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.
Abedin S; Hamadani M
J Exp Pharmacol; 2020; 12():549-557. PubMed ID: 33273867
[TBL] [Abstract][Full Text] [Related]
11. Outcomes and Predictors of Response in Steroid-Refractory Acute Graft-versus-Host Disease.
Rashidi A; DeFor TE; Holtan SG; Blazar BR; Weisdorf DJ; MacMillan ML
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2297-2302. PubMed ID: 31325587
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease.
Pidala J; Kim J; Roman-Diaz J; Shapiro J; Nishihori T; Bookout R; Anasetti C; Kharfan-Dabaja MA
Ann Transplant; 2010; 15(4):21-9. PubMed ID: 21183872
[TBL] [Abstract][Full Text] [Related]
13. Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis.
Schmitt T; Luft T; Hegenbart U; Tran TH; Ho AD; Dreger P
Bone Marrow Transplant; 2011 Apr; 46(4):580-5. PubMed ID: 20562925
[TBL] [Abstract][Full Text] [Related]
14. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
Margolis J; Vogelsang G
Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
[TBL] [Abstract][Full Text] [Related]
15. Treatment options in steroid-refractory acute graft-versus-host disease following hematopoietic stem cell transplantation.
Kim SS
Ann Pharmacother; 2007 Sep; 41(9):1436-44. PubMed ID: 17684033
[TBL] [Abstract][Full Text] [Related]
16. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit.
Ragon BK; Mehta RS; Gulbis AM; Saliba RM; Chen J; Rondon G; Popat UR; Nieto Y; Oran B; Olson AL; Patel K; Hosing CM; Qazilbash MH; Shah N; Kebriaei P; Shpall EJ; Champlin RE; Alousi AM
Bone Marrow Transplant; 2018 Mar; 53(3):315-325. PubMed ID: 29269797
[TBL] [Abstract][Full Text] [Related]
17. Limited benefit of pentostatin salvage therapy for steroid-refractory grade III-IV acute graft-versus-host disease.
Alam N; Atenafu EG; Tse G; Viswabandya A; Gupta V; Kim D; Lipton JH; Messner HA; Kuruvilla J
Clin Transplant; 2013; 27(6):930-7. PubMed ID: 24304375
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
